Recombinant human erythropoietin (rHuEPO) is available for correcting anemia.
Introduction
Anemia is one of the adverse outcomes in some conditions including End-Stage Renal Disease (ESRD). 1 There are many different causes for anemia in patients on maintenance hemodialysis, among which lack of folate and B12 vitamin, gastrointestinal bleeding, iron deficiency, serious inflammations and erythropoietin deficiency are of profound importance. 2, 3 When renal function is significantly impaired or if there is no other possible cause for anemia other than chronic kidney disease, erythropoietin deficiency should be considered as underlying cause of anemia. In such cases treatment with erythropoiesis-stimulating agents (ESAs) should be considered. If remain untreated, anemia can drastically impair the patient's quality of life and lead to cardiac complications. [4] [5] [6] [7] [8] Some of associated cardiovascular complications due to anemia, such as left ventricular hypertrophy and fibrosis, may be irreversible. 9 Therefore, prompt intervention to correct hemoglobin level should be considered. ESAs such as erythropoietin are amongst the most widely used agents in correcting renal anemia. 7, [10] [11] [12] [13] [14] [15] The role of recombinant human erythropoietin alpha, as an ESA, in the correction and maintenance of hemoglobin values in patients with ESRD, 16 cancer associated anemia with low levels of endogenous erythropoietin, 17 and HIV positive patients under cytotoxic treatment, has been widely studied for correcting anemia in ESRD patients. 18 In patients on maintenance hemodialysis hemoglobin levels must be maintained more than 11 g/dL and hematocrit values must be maintained above 33% according to the European Best Practice Guidelines (EBPG) for the management of anemia in patients with chronic kidney disease, 19 or in the range of 11-12 g/dL according to National Kidney FoundationKidney Disease Outcome Quality Initiative guidelines (NKF-KDOQI). 20 PDpoetin is a brand of recombinant human erythropoietin alpha produced in Iran by Pooyesh Darou pharmaceuticals. 21 This drug has successfully passed clinical trial phases I-III; 21, 22 it has been approved by Food and Drug Department of Ministry of Health and Medical Education of Iran. In a controlled trial on its immunogenicity and eliciting anti-rHuEPO antibody, it has been shown that while administered subcutaneously, there is no significant difference between the immunogenicity levels of PDpoetin and Eprex (Janssen, Australia), another well-known and widely used brand of rHuEPO. 23 The aim of this study is to scrutinize effectiveness and possible side effects of PDpoetin in a post marketing surveillance study.
Materials and Methods

Study design
In the current multicenter, open-label, uncontrolled clinical trial 501 patients receiving PDpoetin in daily practice from different centers around Iran − namely Qom, Sari, Tehran, and Mashhad − were enrolled from the February 2011 since the July, 2011. Each patient received 50-100 IU/kg of PDpoetin, 3 times weekly subcutaneously. If a patient did not respond to initial dose within 4 weeks, doses doubled for each administration. When the ferritin levels was <100 ng/mL or the TSAT was <20%, 100 mg of iron over each of the next 10 hemodialysis sessions and then every 2 weeks thereafter was administered intravenously. When subsequent iron parameters remained below these values, a repeat loading of 100 mg after the next 5 hemodialysis sessions was given.
Recombinant human erythropoietin and other medications
The rHuEPO provided as PDpoetin by Pouyesh Darou Pharmaceuticals, Islamic republic of Iran produced in the Chinese hamster ovary (CHO) cells. The rHuEPO preparation was formulated in sterile buffered saline solution containing 0.25% human serum albumin. Intravenous iron was given as Venofer (Aspen Pharmacare, Australia).
Inclusion criteria and exclusion criteria
Patients on maintenance hemodialysis at least 3 months, Hct<30% or Hgb<11 g/dL, without any serious inflammatory problems (CRP<30 mg/L) and serum ferritin 100 ng/mL or TSAT 20% were included in this study. Patients with BP 180/110, Hct 30% or Hb level 11 g/dL, malignancies, cerebrovascular accident (CVA) and symptomatic Ischemic Heart Disease (IHD) were excluded from this study. Patients were excluded from the study after enrollment and during the study if they had seizures, receive renal transplantation or blood transfusion, changed the modality of dialysis, established systemic or vascular access infection, vascular access thrombosis, CVA, or uncontrolled hypertension and died.
Ethical considerations
All patients signed informed consent form to take part in this study. Helsinki Declaration criteria and International Ethical Guidelines for Biomedical Research involving Human Subjects were respected. 24 
Data collection
Data about clinical trial were gathered by directly examining patients and recording the changes in questionnaire by examining physician. Demographic information including age and gender, and common clinical manifestations and patient's profile such as blood pressure (BP), past medical history including ischemic heart disease, CVA, malignancies, hypertension, and blood chemistry parameters consisting of C-reactive protein (CRP, qualitative method), monthly iron parameters including ferritin, serum iron, transferrin saturation (TSAT), basal and weekly hematocrit-hemoglobin (Hct-Hgb) measurements following subcutaneous PDpoetin administration were recorded carefully. Serum samples were collected from poor responders to test for anti-erythropoietin antibodies.
Statistical analysis
The results of the quantitative variables are expressed as mean values ± standard deviation (SD) and those of qualitative variables as proportions. Statistical analysis was carried out by SPSS software (version 16, IBM Corporation, New York, USA). The effect of PDpoetin on variables was modeled using linear mixed model analysis. P<0.05 was assumed to be significant.
Results
Demographic information
Among those recruited for current study 501 patients completed the study and were included in the analysis of data. 20 patients were lost to follow up due to the following causes: 8 patients were excluded because of at least one of the following causes like hypertension, infection and deep vein thrombosis, 7 patients died of unrelated causes, and 5 patients changed their location. The mean age of participants included in data analysis in all centers was 50.9±16.2 years. 48.7% of patients were female. Underlying causes of CKD in our study population were dominated by hypertension by 30.5% of all cases, followed by diabetes (26.4%). The overall cause of renal insufficiency in our study population is depicted in Figure 1 .
Dose of recombinant human erythropoietin
rHuEPO dose titration was done according to previous studies. 21, 22 Briefly, patients received 50 U of rHuEPO per kg bodyweight per session at the beginning. The dosage was then titrated according to the response, increasing the dose by 50% when the increase in Hct was <2% over a 2 to 4-week period, and decreasing the dose by 25% when the increase in Hct was >8% over a period of 4 weeks.
Hemoglobin and hematocrit changes
Our study showed about 1.7±0.6 g/dL of hemoglobin increase in patients after 4 months of treatment with PDpoetin. The mean hemoglobin level in our study was 9.29 (±1.43) at the beginning of study and reached 10.9 (±2.23) at the end of the study (P<0.001) (Figure 2 ). Mean hematocrit percent values raised from 29.31 (±4.56) at the beginning of study to 32.05 (±6.19) after 4 months of PDpoetin administration (Figure 3 ; Table 1 ). In 49% of our patients, anemia was corrected according to the EBPG for the management of anemia in patients with chronic renal failure or NKF-KDOQI and reached more than 11 gr/dL which is the target level of hemoglobin in the current study. 19, [25] [26] [27] [28] Iron metabolism was maintained at acceptable level ( Table 2 ).
Hemorheologic disturbances
In the current study no blood electrolyte change attributable to use of PDpoetin was observed (Table 3) . High blood pressure was observed in 0.6% of patients, while 5.6% of patients showed mild to moderate increases in their blood pressure. Overall less than 1% of our patients showed hemorheologic disturbances in mild to severe levels.
Safety
Other complications including vertigo,
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[page 41] Figure 1 . The underlying cause of chronic kidney disease in our study population. Hypertension is the first known underlying cause of renal failure (30.5%) in patients in the current study, followed by diabetes (26.4%), and glomerulonephritis (8.4%). About 3.5% of our patients with end-stage renal disease were suffering from both diabetes and hypertension, while causes of renal failure in 31.2% of our patients were unknown. lethargy, fever, headache, myalgia, and fatigue were observed with low incidence rate. Totally 97.8% of patients did not show any of the aforementioned symptoms, 2% showed mild to moderate adverse symptoms, and 0.2% of patients showed severe forms of these adverse reactions. Severe pain or other reactions like bruising or inflammation on the site of administration (injection) observed in 0.8% of patients.
Anti-epoetin immunological reaction resulting in Pure Red Cell Aplasia (PRCA) was not observed in the patients included in this study after subcutaneous (s.c.) administration of PDpoetin. Testing for anti-erythropoietin antibodies in poor responders showed no case of raising antibodies against PDpoetin. Most of the patients had improper dietary habits and many of the cases of treatment failure could be attributed to these inappropriate dietary habits.
Discussion
Taking into account that this study is an uncontrolled and multicenter trial in a country with its especial culture, and many socio-economical factors associated with treatment, access to treatment, dietary habits, patient follow-up and adherence to therapy must be considered in the interpretation of the data. According to the EBPG for the management of anemia in patients with chronic renal failure or NFK-DOQI our results supported the efficacy of PDpoetin in the treatment of anemia in patients on maintenance hemodialysis. 19, 20 During four months of treatment about half of the patients reached the target level of 11 g/dL of hemoglobin. However, the evidence from current study is not enough to compare the efficacy of the PDpoetin to other brands, whereas many factors such as dietary habbits and hemodialysis adequacy may affect the results. [29] [30] [31] These factors have been studied in comparative studies of PDpoetin with Eprex and the studies showed similar efficacy of these two brands in hemoglobin maintenance in hemodialysis patients. 21, 22 Article Results of the current study are consistent with previous observations regarding immunogenicity of PDpoetin after s.c. administration. 23 Administration of PDpoetin is via s.c. route, while the recommended route of administration for ESAs in patients on dialysis is through intravenous (i.v.) route. S.c. administration is only recommended in patients not on dialysis because of lack of readily available i.v. access. Efficacy of PDpoetin in ESRD patients on maintenance hemodialysis has been proven in controlled trials. Data from current study is consistent with results from previous studies. 20, 21 In terms of safety, our study proved the safety of PDpoetin for clinical use in ESRD patients on maintenance hemodialysis.
Conclusions
Our study confirmed the efficacy of PDpoetin in treatment of anemia in patients on maintenance hemodialysis. Also, our study demonstrated that PDpoetin use is not associated with any significant side effects attributable to the use of this agent. 
